Biological sex defines regulatory T-cell reprogramming trajectories in immune-related adverse events and autoimmunity
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 and CTLA-4 pathways have revolutionized cancer therapy but are frequently associated with immune-related adverse events (irAEs), i.e. inflammatory toxicities that resemble classical autoimmune diseases and reflect disruption of peripheral tolerance. Reg...